

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
24 October 2024 (24.10.2024)



(10) International Publication Number
WO 2024/220641 A1

(51) International Patent Classification:

C07D 519/00 (2006.01) A61P 29/00 (2006.01)
C07D 471/04 (2006.01) A61K 31/4375 (2006.01)
A61P 25/00 (2006.01) A61K 31/519 (2006.01)

(21) International Application Number:

PCT/US2024/025156

(22) International Filing Date:

18 April 2024 (18.04.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/496,811 18 April 2023 (18.04.2023) US
63/610,209 14 December 2023 (14.12.2023) US

(71) Applicant: VANDERBILT UNIVERSITY [US/US]; 305
Kirkland Hall, 2201 West End Avenue, Nashville, Ten-
nessee 37240 (US).

(72) Inventors: LINDSLEY, Craig W.; 9281 Wardley Park
Lane, Brentwood, Tennessee 37027 (US). ENGERS, Dar-
ren W.; 1744 Stillwater Circle, Brentwood, Tennessee
37027 (US). TEMPLE, Kayla J.; 2213 Caleb Drive,
Spring Hill, Tennessee 37174 (US). GREGRO, Alison
R.; 4029 Ethan Avenue, Mount Juliet, Tennessee 37122
(US). LONG, Madeline F.; 4110 Idaho Avenue, Nashville,
Tennessee 37209 (US). RICHARDSON, Alexa E.; c/o
Vanderbilt University, 305 Kirkland Hall, 2201 West End
Avenue, Nashville, Tennessee 37240 (US). RABENOLD,
Lake E.; c/o Vanderbilt University, 305 Kirkland Hall,
2201 West End Avenue, Nashville, Tennessee 37240 (US).

(74) Agent: CARROLL, William A. et al.; Michael Best &
Friedrich LLP, 790 N. Water Street, Suite 2500, Milwaukee,
Wisconsin 53202 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))



WO 2024/220641 A1

(54) Title: 1,6-NAPHTHYRIDINE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 USEFUL FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS

(57) Abstract: 5,6,7,8-Tetrahydro-1,6-naphthyridines substituted in the 6-position with 6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one, furo[3,4-b]pyridin-5(7H)-one, 6,7-dihydro-5H-cyclopenta[b]pyridin-5-one, or [1,2,4]triazolo[4,3-a]pyrimidin-3(2H)-one, and deriva-
tives thereof are positive allosteric modulators of the muscarinic acetylcholine receptor M₄ (mAChR M₄) and may have use in treating
neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction.